Interferon-γ production following nucleofection was more readily detected in response to BMI-1 in the patients with colorectal and prostate cancer, whereas the HCC patients tended to have stronger responses to EZH2. This dominant response to EZH2 in the HCC group was also apparent with the ELISPOT assays, where the magnitude of the responses to the EZH2 peptides was generally greater than those to BMI-1. This evidence concerns the gene EZH2 and prostate carcinoma.